Year: 2026
Type: article
Study design: Case Report
Abstract: Down syndrome (DS), caused by trisomy 21 in ~95% of cases, carries three copies of the chromosome 21 interferon receptor cluster (IFNAR1, IFNAR2, IFNGR2, and IL10RB), leading to a constitutive, mild interferonopathy across types I, II, and III signalling. Down syndrome regression disorder (DSRD) is a devastating neuro-regression occurring between 10 and 30 years. A sub-group shares immunological and neuroimaging features with the monogenic type I interferonopathies, though the mechanism differs: trisomy 21 confers receptor-level over-responsiveness rather than ligand excess. DSRD remains a diagnosis of exclusion but commonly arises on a background of pre-existing neurodevelopmental or neuropsychiatric comorbidity, so identifying a comorbidity does not itself exclude it. Both adolescents described here presented with severe neuropsychiatric regression, symmetric basal ganglia mineralization, and an isolated elevation of the interferon-stimulated gene IFI27. No commissioning pathway for DSRD immune-directed therapy exists in the United Kingdom (UK). Approximately 21 months after onset, intravenous immunoglobulin (IVIG) was commenced in both, for the first time in the UK: 2 g/kg loading then eight monthly doses of 1 g/kg. Nine doses produced partial but clinically meaningful multidomain improvement without serious adverse events. Serial IFI27 fell in both but remained above the reference interval throughout; it did not track clinical response. These descriptive observations require confirmation in controlled studies. Inability to access workup and treatment is a health inequity; early recognition and a multidisciplinary approach spanning neurology, psychiatry, and immunology are needed.
Source: Frontiers in Immunology
Authors: Marios Kaliakatsos, Iek Leng Cheng(Writing – original draft, Writing – review & editing), Ellie Simmonds(Writing – original draft, Writing – review & editing), Ashley Liew(Investigation, Writing – original draft, Writing – review & editing), Olivier van den Broucke, Kshitij Mankad(Investigation, Visualization, Writing – original draft, Writing – review & editing), Abinaya Seenivasan(Writing – original draft, Writing – review & editing), Ella Rachamim(Writing – original draft, Writing – review & editing), Shahid Zaman(Writing – original draft, Writing – review & editing), Jessica Laxaman(Writing – original draft, Writing – review & editing), Paramala Santosh(Writing – original draft, Writing – review & editing), Eleanor J. Molloy(Writing – original draft, Writing – review & editing), Kimberly Gilmour(Writing – original draft, Writing – review & editing), Mark Davis(Writing – original draft, Writing – review & editing), Arlene Barcenilla(Writing – original draft, Writing – review & editing), Konstantinos Vazouras(Writing – original draft, Writing – review & editing), Reem Elfeky(Writing – original draft, Writing – review & editing), Maaike A. Kusters
Institutions: Great Ormond Street Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, University College London, South London and Maudsley NHS Foundation Trust, Evelina London Children's Healthcare, Hertfordshire Community NHS Trust, Royal Manchester Children's Hospital, Royal Free London NHS Foundation Trust, University of Cambridge, Cambridgeshire and Peterborough NHS Foundation Trust, National Health Service, King's College London, Trinity College Dublin
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236767680
